Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

Y-mAbs to Present at the Oppenheimer 35?? Annual Life Sciences Conference

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

Y-mAbs Provides Strategic Business Update and 2025 Priorities

Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting